COMBINATION MEDICAMENTS COMPRISING HLA FUSION PROTEINS

Abstract: the present invention relates to combination medicaments comprising (human leukocyte antigen) soluble hla heavy chain polypeptides, and an inhibitor of the interaction between cd47 and signal regulatory protein alpha (sirp□□□□for use in treating cancer. further aspects of the invention relate to an inhibitor of the interaction between cd47 and sirp□, for use in patients receiving treatment with a soluble hla heavy chain polypeptide according to the invention.

Inventor(s): Osiris MARROQUIN BELAUNZARAN, Marco GUALANDI, Anahita RAFIEI

CPC Classification: C07K14/70539 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250163129